Spearheaded efforts to develop enabling technologies for precision medicine.Focus area: autoimmune and inflammatory diseases• Developed and implemented qPCR-based biomarker strategy for patient stratification• Pioneered mobile qPCR for point-of-care therapeutic management• Developed lateral flow test utilizing novel peptide nucleic acid capture technology• Led IND-enabling in vitro preclinical pharmacology activities• Pioneered LNP-mRNA-based modality to deliver protein therapeutics (engineered DNASE1L3 for neutrophil extracellular trap [NET] degradation and elimination)• Led in silico design efforts directed at neutrophil modulation via antagonism of G-CSF receptor• Led indication expansion efforts aimed at therapeutic NET degradation in metastatic cancer

Providing end-to-end Discovery services from Target ID & Validation to IND. * Integrated in-house Biology, Synthetic & Medicinal Chemistry, DMPK, Toxicology * Currently, over 600 Discovery scientists running a diversity of technologies > Exploratory Biology lab in Cambridge, MA > Integrated Discovery & Development Campus, Hyderabad, INDIA > Process labs, Manchester, UK

Startup with unique platform technology for the rapid discovery and development of small molecule therapeutics that act directly on disease-causing RNA.I have been responsible for fundraising, team building, platform development, scientific strategy and all operational activities.

> Led the RNA Editing platform group. Utilizing Wave's proprietary oligonucleotide chemistry as guide molecules to edit RNA targets via endogenous adenosine deaminases acting on RNA (ADARs).> Co-led Wave's In Vivo Biology team. • Managed the full on-boarding life cycle for new contract research organizations (CROs) • Negotiated license agreements for in vivo disease models, managed master service agreements (MSA) and statements of work (SOW) • Created and implemented new project management tool to track and integrate work and processes • Increased capacity of team via FTE hiring, outsourcing, and contract reconfiguration for existing CROs> Led the Wave postdoctoral program. • Reset the direction and goals of the postdoctoral program with greater emphasis placed on peer-reviewed publication(s), career insight and development, succeeding in a matrix management environment, broadening and innovating platform technology at Wave>Information Technology Steering Committee, Discovery Biology Representative • Launched initiative to build and deploy cloud-based Project Online Web App tools to better manage the project portfolio in key areas> Chairman, Institutional Biosafety Committee

Spearheaded a new effort to directly target RNA in neuromuscular diseases. Project approved at highest level of Research (NIBR New Target Review Committee) triggering broad resource allocation. Early success spawned an institute-wide, transcontinental RNA InitiativeMyotonic dystrophy• Developed both biochemical and biophysical HTS assays to probe the interaction of proteins, LMW compounds, and oligonucleotides with disease-causing repeat sequence RNA. Full-deck (1.5Mio LMW) screen executed collaboratively with HTS group.**Novel chemotype discovered that reverses disease phenotype in cellular models**• Procured (both academic and for-profit sources), validated, and deployed patient-derived primary cells for phenotypic screens. -Developed high content imaging (HCI)-compatible FISH technique for elucidating repeat sequence RNA. Enabled a HCI foci clearance screen for novel mechanisms of disease phenotype reversal. -Enabled development of pioneering ultrahigh throughput (1536) “Cells-to-Ct” qPCR alternative splicing readout.**HCI and alternative splicing assays are now routinely deployed for both HTS and follow-up**• Project sub-team leader for NMR and biophysics follow-up team. Facilitated the design of NMR-ready, model RNA structures.**High resolution NMR data has been acquired and used to elucidate binding mode of lead compounds**• Collaborated with computational biology group to execute virtual screen using a reductionist RNA flexible receptor model.**Candidate fragments confirmed as selective binders using RNA molecular beacon thermal melts**

Muscle atrophy and Fascioscapulohumeral Dystrophy• Piloted early discovery efforts aimed at utilizing EGF-family ligands to reverse muscle atrophy using HCI readouts.• Introduced hydrodynamic injection technology and worked with in vivo muscle biology colleagues to deliver neuregulin to muscle.• Validated microsatellite contraction-mediated changes in muscle gene expression profile (FSHD) via qPCR.**Project fully adopted by Musculoskeletal Disease Area. Compounds recently discovered from parallel indication are now poised to enter clinical trials**

• Co-founded a proteomics-based target identification platform (TIP)• Managed TIP cell biology and biochemistry responsible for small molecule-based affinity capture and identification of novel targets• Supported numerous projects/disease areas via target-finding and mechanism of action studies• Co-authored book chapter on "Kinase Inhibitor Profiling Using Chemoproteomics"

• Co-established Academic HTS Partnership Program and served as scientific liaison• Built biology lab with early stage discovery capabilities including biochemical and cell-based assay development, MTS/HTS, multiplex assays (Luminex xMAP)• Designed and executed synthetic lethality screen for p53-mutant cancers leading to launch of internal institute-wide program• Set up and managed academic collaboration centered on early discovery efforts for Friedreich ataxia

• Supported internal discovery projects by developing and implementing HTS-amenable biochemical assays• Led HTS efforts and coordinated cross-disciplinary information dissemination• Developed thermal shift technique for optimizing protein stability enabling project team to determine the first 3-dimensional structure of ZAP kinase

• Invented high throughput method to stabilize proteins and facilitate protein crystallization• Granted five U.S. patents

• Managed all ThermoFluor® HTS. Led team that discovered novel hdm2/p53 antagonists• Served as co-project team leader, Bristol-Myers Squibb (BMS) collaboration• Innovated functional genomics application of ThermoFluor® technology• Decrypted BMS microbial target proteins• Expanded ThermoFluor® HTS and Biophysics Groups to 12 members• Managed and maintained 3DP compound archive

• Developed the ThermoFluor® technology, a high throughput, thermodynamic measurement of protein stability• Characterized protein-drug interactions via ITC and DSC